Journal of Medicinal Chemistry p. 4913 - 4925 (2016)
Update date:2022-07-29
Topics:
Wang, Heng-Yen
Qin, Yajuan
Li, Huiying
Roman, Linda J.
Martásek, Pavel
Poulos, Thomas L.
Silverman, Richard B.
Neuronal nitric oxide synthase (nNOS) is an important therapeutic target for the treatment of various neurodegenerative disorders. A major challenge in the design of nNOS inhibitors focuses on potency in humans and selectivity over other NOS isoforms. Here we report potent and selective human nNOS inhibitors based on the 2-aminopyridine scaffold with a central pyridine linker. Compound 14j, the most promising inhibitor in this study, exhibits excellent potency for rat nNOS (Ki = 16 nM) with 828-fold n/e and 118-fold n/i selectivity with a Ki value of 13 nM against human nNOS with 1761-fold human n/e selectivity. Compound 14j also displayed good metabolic stability in human liver microsomes, low plasma protein binding, and minimal binding to cytochromes P450 (CYPs), although it had little to no Caco-2 permeability.
View MoreContact:86-379-63338609
Address:Jiudian Village,Deting Town,Song County,Luoyang
Neworld Chemical Co., Ltd Shanghai(expird)
Contact:+86-21-62202658
Address:11F, Blvd 2, No. 1969 PuXing Rd, Shanghai
Dongguan Albiya Energy Science and Technology Co.,Ltd
Contact:+86-769-22181286
Address:Huanan Industial Park, Dongguan,China
Laizhou City Laiyu Chemical CO.,Ltd
Contact:+86-535-2719337/2719339
Address:Chenggang road zhuyou laizhou City Shangdong China
Springchem New Material Technology Co.,Limited
website:http://www.spring-chem.com
Contact:86-21-62885108
Address:602B, Building 1, No. 641, Tianshan Road
Doi:10.1055/s-2001-16773
(2001)Doi:10.1002/chem.201304063
(2014)Doi:10.1039/f19827800347
(1982)Doi:10.1016/S0040-4039(01)84944-3
(1972)Doi:10.1021/ja01609a033
(1955)Doi:10.1016/j.jinorgbio.2010.03.013
(2010)